ArticleBMJ open2016
Toxoplasma gondii seroprevalence in the Portuguese population: comparison of three cross-sectional studies spanning three decades.
Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Worldwide Seroprevalence and Risk Factors of Toxoplasma gondii Exposure Among Students: A Systematic Review and Meta-Analysis.Zoonoses and public health · 2026Pooled it
- Evolution ofJournal of parasitology research · 2026Review
- Anti-Pathogens (Basel, Switzerland) · 2023Review
- Seroprevalence ofEpidemiology and infection · 2023Article
- Antenatal Screening for Toxoplasmosis and Rubella in Saudi Arabia: Assessing the Need for Screening.Journal of multidisciplinary healthcare · 2023Article
- Screening for the Detection ofLife (Basel, Switzerland) · 2022Article
- Seroprevalence and Risk Factors forAnimals : an open access journal from MDPI · 2022Article
- A Cross-Sectional Study of Knowledge on Ownership, Zoonoses and Practices among Pet Owners in Northern Portugal.Animals : an open access journal from MDPI · 2021Article
- Prevalence of Antibodies toPathogens (Basel, Switzerland) · 2021Article
- National perinatal survey demonstrates a decreasing seroprevalence ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Review
- Catastrophic consequences: can the feline parasite Toxoplasma gondii prompt the purrfect neuroinflammatory storm following traumatic brain injury?Journal of neuroinflammation · 2020Review
- Seroprevalence of Toxoplasma gondii infection among women of childbearing age in an endemic region of Romania, 2016-2018.Parasite (Paris, France) · 2020Article
- Seroepidemiology of Infection withIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToxoplasma gondii is an obligate intracellular protozoan infecting up to one-third of the world's population, constituting a life threat if transmitted from mother to child during pregnancy. In Portugal, there is a lack of knowledge of the current epidemiological situation, as the unique toxoplasmosis National Serological Survey was performed in 1979/1980.
methodsWe studied the seroprevalence trends in the Portuguese general population over the past 3 decades, by assessing chronological spread cross-sectional studies, with special focus on women of childbearing age, by age group, region and gender.
resultsThe T. gondii overall seroprevalence decreased from 47% in 1979/1980 to 22% (95% CI 20% to 24%) in 2013. Generally, we observed that the prevalence of T. gondii IgG increased significantly with age and it decreased over time, both in the general population and in the childbearing women (18% prevalence in 2013).
conclusionsThe scenario observed for the latter indicates that more than 80% of childbearing women are susceptible to primary infection yielding a risk of congenital toxoplasmosis and respective sequelae. Since there is no vaccine to prevent human toxoplasmosis, the improvement of primary prevention constitutes a major tool to avoid infection in such susceptible groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.